REG - Convatec Group PLC - Convatec announces Karim Bitar has passed away

ConvaTecAnnouncement

Today 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa9770Ea&default-theme=true

RNS Number : 9770E  Convatec Group PLC  27 October 2025

27 October 2025

Convatec Group Plc

("Convatec" or "the Company")

Convatec announces that Karim Bitar has passed away

 

London, UK, 27 October 2025: The Board of Directors of Convatec is very sorry
to announce that Convatec's CEO, Karim Bitar, who has been on medical leave of
absence since 4 August 2025, has sadly passed away.

 

Colleagues at Convatec are deeply saddened by this devastating news. Our
sincerest sympathies are with Karim's wife and family, and we extend our
condolences to them.

 

As previously announced, interim leadership arrangements remain in place and a
further announcement will be made in due course.

 

This announcement includes inside information as defined in Article 7 of the
Market Abuse Regulation No. 596/2014 as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018. The person responsible
for making this announcement is James Kerton, Company Secretary, Convatec
Group plc: cosec@convatec.com

 

Media: MediaRelations@convatec.com

 

Investor Relations: IR@convatec.com

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

Classification: 2.2 Inside Information disclosed under article 7 of the Market
Abuse Regulation

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide our products and services in around 90
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Convatec's revenues in
2024 were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com
(http://www.convatecgroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFEFIALDFIE



            Copyright 2019 Regulatory News Service, all rights reserved